Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Biochem Biophys Res Commun ; 503(4): 2206-2211, 2018 09 18.
Artigo em Inglês | MEDLINE | ID: mdl-29953857

RESUMO

Within the extracellular domains of metastasis suppressor CD82, the large extracellular loop (EC2) has received much of the attention and its structure and function have been studied in detail. However, little attention has been given to the small extracellular loop (EC1 domain). To investigate the function role of EC1 in metastasis suppression of CD82, the peptide mimicking EC1 amino acid sequence (EC1-mP) was synthesized and its effect on cancer cells behavior was examined. Here, we reported that EC1-mP strongly inhibited cancer cell migration in vitro, attnuated the ability of cancer cells adhesion to fibronectin, and induced the apoptosis. Furthermore, the EC1-mP was showed to supprese the expressions of integrins α5 and ß1, as well as decreased the phosphorylation of FAK and expression of ILK in SW620 cells. Taken together, these results demonstrate that this small peptide has the functional role of CD82 intact molecule. This novel finding will improve our understanding of the mechanism by which CD82 inhibits metastasis, and suggested that EC1 mimic peptide may be a promising candidate for developing anti-metastasis drugs.


Assuntos
Proteína Kangai-1/genética , Peptídeos/farmacologia , Antineoplásicos/química , Antineoplásicos/farmacologia , Apoptose/efeitos dos fármacos , Adesão Celular/efeitos dos fármacos , Linhagem Celular Tumoral , Movimento Celular/efeitos dos fármacos , Humanos , Integrina alfa5/efeitos dos fármacos , Integrina beta1/efeitos dos fármacos , Mimetismo Molecular , Metástase Neoplásica , Domínios Proteicos , Transdução de Sinais/efeitos dos fármacos
2.
Mol Med Rep ; 8(2): 655-61, 2013 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-23778885

RESUMO

The aim of the present study was to determine the molecular mechanism by which the hepatocyte growth factor (HGF) receptor (cMet) regulates lymphatic metastasis in hepatocellular carcinoma. Mouse hepatoma ascites cell lines with different lymph node metastatic potentials, Hca­F (high metastatic potential) and Hca­P (low metastatic potential), were cultured in vitro. Cells were treated with HGF, fibronectin (FN) and laminin (LN), and the phosphorylated tyrosine residues of cMet and the activities of intracellular phospholipase Cγ/diacylglycerol/protein kinase C (PLCγ/DAG/PKC) and phosphoinositol­3­kinase/protein kinase B (PI3K/AKT) signaling pathways were analyzed comparatively in the two cell lines using western blot analysis and migration assays. Following HGF treatment, the phosphorylation of cMet at Tyr 1313 and 1365 in Hca­F cells was higher, while the phosphorylation of cMet at Tyr 1349 was lower than that in Hca­P. The activity of PLCγ/DAG/PKC was increased in Hca­F cells compared with Hca­P cells, whereas the activity of PI3K/AKT was reduced. After FN treatment, the phosphorylation of cMet at Tyr 1313 and the activity of the PLCγ/DAG/PKC signaling pathway was increased in Hca­F cells compared with Hca­P cells. Following LN treatment, the phosphorylation of cMet at Tyr 1365 and the activity of PLCγ/DAG/PKC was higher in Hca­F cells than in Hca­P cells. Results of the current study indicate that a number of ligands stimulate the phosphorylation of cMet at various tyrosine residues, activating different signaling transduction pathways. In addition, the same ligand was observed to phosphorylate different tyrosine residues on cMet in the two cell lines, as well as activate different intracellular signaling transduction pathways. After cMet is activated, various tyrosine residues are phosphorylated, leading to the activation of the PI3K/AKT and PLCγ/DAG/PKC signaling pathways to different extents in the two cells lines. These results may be important in determining the lymph node metastatic potentials of the two cell lines.


Assuntos
Carcinoma Hepatocelular/metabolismo , Carcinoma Hepatocelular/patologia , Neoplasias Hepáticas/metabolismo , Neoplasias Hepáticas/patologia , Proteínas Proto-Oncogênicas c-met/metabolismo , Animais , Linhagem Celular Tumoral , Movimento Celular/efeitos dos fármacos , Fibronectinas/farmacologia , Fator de Crescimento de Hepatócito/farmacologia , Humanos , Linfonodos/patologia , Metástase Linfática , Camundongos , Fosfatidilinositol 3-Quinases/metabolismo , Fosfolipase C gama/metabolismo , Fosforilação/efeitos dos fármacos , Proteína Quinase C/metabolismo , Proteínas Proto-Oncogênicas c-akt/metabolismo , Transdução de Sinais/efeitos dos fármacos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA